U.S. Banks Stock News

NYSE:CRGY
NYSE:CRGYOil and Gas

Crescent Energy (CRGY) Is Up 5.2% After Record Q1 Output Amid Net Loss Expansion Has The Bull Case Changed?

Crescent Energy reported past first-quarter 2026 results with revenue of US$1,182.83 million and a net loss of US$419.85 million, while delivering record average production of 341 MBoe/d. Despite the larger loss, management emphasized record volumes, operational efficiency, and successful integration of newly acquired Permian assets as key drivers of the quarter’s operational outperformance. We’ll now examine how this record production and operational efficiency update affects Crescent...
NYSE:NFG
NYSE:NFGGas Utilities

How Softer Output and Line N Expansion At National Fuel Gas (NFG) Has Changed Its Investment Story

In its recent past fiscal second quarter update, National Fuel Gas reported a 3% natural gas production decrease at Seneca Resources due to weather-related delays and natural declines, while moving forward with upgrades to its Line N pipeline to carry more Marcellus and Utica shale gas. This combination of softer near-term production and added pipeline capacity highlights how the company is balancing short-term operational challenges with longer-term infrastructure growth in its core...
NasdaqGS:LCID
NasdaqGS:LCIDAuto

Lucid And Uber Deal Recasts Funding Needs And Robotaxi Growth Hopes

Lucid Group (NasdaqGS:LCID) is deepening its partnership with Uber, with a US$1.05b capital raise and Uber lifting its stake to 11.5%. Uber has committed to purchase 35,000 Lucid vehicles as part of the agreement, linking Lucid more closely to future autonomous mobility platforms. The news comes as Lucid shifts toward operational turnaround under new CEO Silvio Napoli and addresses a stop sale on its Gravity model tied to supply chain issues. Lucid is also planning a push into more...
NYSE:THG
NYSE:THGInsurance

Should Hanover’s Expanded Buyback and Specialty Coverage Shift Require Action From The Hanover (THG) Investors?

The Hanover Insurance Group recently approved a new US$700 million share repurchase authorization and expanded its motorcycle and off-road vehicle insurance offerings into several additional U.S. states, enhancing coverage features and availability. This combination of an enlarged buyback program and broader specialty product footprint highlights the company’s emphasis on capital deployment alongside deeper multi-product relationships with policyholders. We’ll now examine how Hanover’s...
NasdaqGM:IVVD
NasdaqGM:IVVDBiotechs

Invivyd (IVVD) Q1 Loss Of US$41.4 Million Reinforces Bearish Unprofitability Narrative

Invivyd (IVVD) has released its Q1 2026 numbers with revenue of about US$13.7 million and a basic EPS loss of US$0.13, alongside a trailing 12 month net loss of US$77.6 million. The company has seen revenue move from US$25.4 million in Q4 2024 on a trailing 12 month basis to US$55.9 million in the latest trailing period, while trailing basic EPS has shifted from a loss of US$1.43 to a loss of US$0.35. Investors are therefore looking at a business where top line momentum is meeting still heavy...
NasdaqGS:TYRA
NasdaqGS:TYRABiotechs

Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?

Tyra Biosciences, Inc. recently reported first-quarter 2026 results showing a wider net loss of US$39.31 million and basic loss per share of US$0.64, while highlighting progress across three Phase 2 trials for its lead candidate dabogratinib and a cash balance of US$383.5 million supporting operations into the second half of 2028. An interesting angle for investors is how Tyra’s “dabogratinib 3×3” plan concentrates resources on three FGFR3-driven indications, potentially shaping its future...
NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements

Humacyte (HUMA) is back in focus after Q1 2026 results highlighted continued losses alongside restructuring moves, new leadership, fresh international agreements, and upcoming clinical readouts that could influence how investors view the stock. See our latest analysis for Humacyte. The share price has been volatile, with a 1 month share price return of 26.36% but a 1 year total shareholder return that is down 58.48%. This reflects shifting sentiment as investors weigh fresh capital raises,...
OTCPK:RLEA
OTCPK:RLEAAuto Components

Rubber Leaf (OTCPK:RLEA) Turns Q1 EPS Positive Yet Ongoing Losses Challenge Bullish Narratives

Rubber Leaf (OTCPK:RLEA) opened 2026 with Q1 revenue of about US$3.3 million and basic EPS of roughly US$0.01, with the stock trading around US$4.50. Over recent periods, the company has seen quarterly revenue range from US$0 to about US$3.3 million while basic EPS has moved between a loss of roughly US$0.01 and a gain of just under US$0.01. This gives investors a clear view of how sensitive margins have been to shifts in activity levels. See our full analysis for Rubber Leaf. With the...
NYSE:CLVT
NYSE:CLVTProfessional Services

Clarivate (CLVT) Valuation Check After Launch Of Web Of Science Research Intelligence AI Platform

Why Clarivate’s New AI Platform Matters for the Stock Clarivate (CLVT) has launched Web of Science Research Intelligence, an AI-native platform built with research institutions to combine curated data, impact metrics, and workflows across funding, collaboration, and research assessment. For shareholders, this fresh product sits at the heart of Clarivate’s existing research and intellectual property data assets, raising questions about adoption, pricing power, and how it may influence...
NYSE:ADM
NYSE:ADMFood

How Investors Are Reacting To Archer-Daniels-Midland (ADM) Upgraded Earnings Guidance And Stronger Biofuel Margins

In May 2026, Archer-Daniels-Midland reported first-quarter sales of US$20,490 million and net income of US$298 million, modestly above the prior year, raised its full-year adjusted earnings guidance, affirmed a quarterly dividend of US$0.52 per share, and held its annual meeting where all management proposals passed and an environmental reporting proposal was rejected. The earnings beat and guidance increase, underpinned by stronger soybean crush, ethanol and Nutrition margins after U.S...
NYSE:KBH
NYSE:KBHConsumer Durables

Is KB Home (KBH) Using New ENERGY STAR Communities To Recast Its Build‑To‑Order Strategy?

KB Home recently opened several new communities across the U.S., including Stevens Ridge in Marysville, Washington, Sunset Oaks and Madera in Texas, and multiple developments in California and Arizona, offering personalized, ENERGY STAR®-designed homes with prices starting from the mid US$200,000s to the US$590,000s range. These geographically diverse launches, all emphasizing efficiency, health-focused features and extensive buyer personalization, highlight KB Home’s continued push into...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

Does Open Text (OTEX) Tighten Its Focus or Shrink Its Ambition With Vertica Sale And Steady Guidance?

In early May 2026, Open Text Corporation reported third-quarter results showing higher revenue of US$1,282.5 million and net income of US$172.65 million year-on-year, affirmed its 2026 earnings guidance for 1% to 2% revenue growth after adjusting for US$30 million of divested sales, completed the sale of its Vertica business, and confirmed a quarterly dividend of US$0.2750 per share payable on June 19, 2026. By exiting the non-core Vertica analytics unit and directing the proceeds toward...
NasdaqGS:ERAS
NasdaqGS:ERASBiotechs

Assessing Erasca (ERAS) Valuation After ERAS-0015 Patent And Trade Secret Dispute

Erasca (ERAS) is under pressure after disclosing that Revolution Medicines accused its lead candidate ERAS-0015 of patent infringement and trade secret misappropriation, prompting multiple securities law investigations and raising fresh questions about the program’s long term prospects. See our latest analysis for Erasca. The latest legal headlines arrive after a sharp 43.79% decline in the 30 day share price return. This follows a strong year to date share price return of 184.96% and a very...
NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Biogen’s Diranersen Moves To Late-Stage Alzheimer’s Trials And Investor Focus

Biogen (NasdaqGS:BIIB) is advancing its experimental Alzheimer’s drug diranersen into late stage trials after Phase 2 CELIA data. The therapy, an antisense oligonucleotide that targets tau protein, did not meet the study’s primary endpoint but showed strong biomarker changes and signs of cognitive benefit. The decision extends Biogen’s Alzheimer’s efforts beyond amyloid focused treatments and increases attention on its neurology pipeline. For you as an investor, this keeps Biogen in the...
NYSE:MSA
NYSE:MSACommercial Services

Assessing MSA Safety (MSA) Valuation After Recent Share Price Volatility

MSA Safety stock snapshot after recent moves MSA Safety (MSA) has drawn fresh attention after recent price swings, with the stock closing at US$171.24. For investors, the question now is how current valuation aligns with fundamentals. See our latest analysis for MSA Safety. Recent trading has been choppy, with the share price falling 15.2% over the past 90 days but still showing a 5.55% year to date share price return and 8.68% one year total shareholder return. This suggests moderating...
NYSE:GNK
NYSE:GNKShipping

Genco Rejects Diana Tender Offer As Control And Governance Battle Escalates

Genco Shipping & Trading (NYSE:GNK) has rejected an unsolicited tender offer from Diana Shipping Inc. The board voted unanimously against the bid and is urging shareholders not to tender their shares. The rejection comes during an active takeover and proxy contest focused on control, valuation, and governance. For investors watching NYSE:GNK, this board level pushback follows a strong run in the stock, with shares up 33.6% year to date and 82.7% over the past year, closing at $24.63. The...
NYSE:AIT
NYSE:AITTrade Distributors

Does Slower Organic Growth Undermine the Automation and M&A Story at Applied Industrial Technologies (AIT)?

In recent commentary, Applied Industrial Technologies has been flagged for underperformance in its core business, with organic revenue and earnings growth over the past two years trailing industry peers and highlighting a heavier dependence on acquisitions to sustain expansion. This weaker internal growth profile, combined with only modestly projected sales improvement, raises questions about how effectively Applied can balance acquisition-driven growth with the health of its underlying...